# Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Study · id `cardio:ct-nct03459079` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03459079](<https://clinicaltrials.gov/study/NCT03459079>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03459079

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

## Technical summary

Registry record NCT03459079. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-14 (actual); primary completion 2023-04-18 (actual). Results posted on 2024-09-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 128 participants (enrolled count; ClinicalTrials.gov record NCT03459079, source copy `cardio:ctgov-nct03459079-2024-09-19`, retrieved 2026-10-26)
- Started: 2018-08-14 (actual) (ClinicalTrials.gov record NCT03459079, source copy `cardio:ctgov-nct03459079-2024-09-19`, retrieved 2026-10-26)
- Primary completion: 2023-04-18 (actual) (ClinicalTrials.gov record NCT03459079, source copy `cardio:ctgov-nct03459079-2024-09-19`, retrieved 2026-10-26)
- Completion: 2023-06-01 (actual) (ClinicalTrials.gov record NCT03459079, source copy `cardio:ctgov-nct03459079-2024-09-19`, retrieved 2026-10-26)
- Results first posted: 2024-09-19 (ClinicalTrials.gov record NCT03459079, source copy `cardio:ctgov-nct03459079-2024-09-19`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03459079, source copy `cardio:ctgov-nct03459079-2024-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03459079-2024-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
- Condition: Nonalcoholic Fatty Liver Disease (NAFLD)
- Condition: Type 2 Diabetes (T2DM)
- Intervention (Drug): Lanifibranor
- Intervention (Other): Placebo
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: Inventiva Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD (`cardio:pubmed-39824443`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 13eba13391c258f4ff1d9d3f5d02eb84e910673ec0011c734fab48b21504f1c4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
